Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glioma lysate vaccine GBM6-AD
- Development stage
- Discontinued
- Lead developer
- Masonic Cancer Center
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Glioma lysate vaccine GBM6-AD is an investigational allogeneic brain tumor-initiating cell lysate vaccine developed at the University of Minnesota. It is manufactured from the GBM6-AD glioma stem-cell line and presents an undefined repertoire of glioma-associated antigens to induce tumor-reactive cellular immunity, including cytotoxic T-cell responses against antigen-expressing glioma cells. In the Masonic Cancer Center-sponsored Phase 1 DIPG study, it was administered with topical imiquimod and radiation; imiquimod is a separate immune-response-modifying adjuvant and is not part of the vaccine product itself. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/glioma-lysate-vaccine-gbm6-ad))
- Other names
- GBM6-AD lysate protein vaccineGBM-6-AD lysate protein vaccineGBM 6-AD lysate protein vaccineglioma cell lysate vaccine GBM6-ADBTIC lysate-based vaccinetumor lysate vaccine
Beyond the preview
Go deeper on glioma lysate vaccine GBM6-AD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glioma lysate vaccine GBM6-AD.